NK

NantKwest
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.80
-0.29
-2.06%
After Hours: 13.83 +0.03 +0.22% 19:51 07/10 EDT
OPEN
13.98
PREV CLOSE
14.09
HIGH
14.50
LOW
13.60
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
15.34
52 WEEK LOW
1.040
MARKET CAP
1.46B
P/E (TTM)
-20.4991
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NK stock price target is 10.75 with a high estimate of 18.00 and a low estimate of 3.500.

EPS

NK News

More
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 17h ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 1d ago
BIIB, MFGP among premarket gainers
Seeking Alpha - Article · 2d ago
Weekly CEO Buys Highlight
GuruFocus.com · 4d ago
Insider Weekends: With Latest Purchase Harold Hamm Owns 80% Of Continental Resources
Seeking Alpha - Article · 4d ago
The Executive Chairman & CEO of NantKwest, Inc. (NASDAQ:NK), Patrick Soon-Shiong, Just Bought 6.1% More Shares
Simply Wall St. · 07/02 15:24
NantKwest: The Market And The Government Are Missing Out On This Blockbuster
Seeking Alpha - Article · 06/30 01:37
NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
Business Wire · 06/29 21:05

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About NK

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
More

Webull offers kinds of Nantkwest Inc stock information, including NASDAQ:NK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NK stock methods without spending real money on the virtual paper trading platform.